Successful treatment of severe subcutaneous insulin resistance with inhaled insulin therapy.
The potential of inhaled insulin therapy for severe resistance to subcutaneous insulin was tested in a 7-yr old boy with type 1 diabetes mellitus. The efficiency of 1 mg inhaled insulin (Exubera) was examined by a 4-h euglycemic clamp study. During the clamp, the glucose infusion rate started to increase 25 min after inhalation and peaked 120 min after inhalation. Subsequently, a trial of inhaled insulin monotherapy was initiated consisting of pre-meal inhalations and one inhalation during the night. Since glycemic control remained fair (HbA1c approximately 8.5%), this therapy was continued. Over the ensuing 18 months, mild keto-acidosis occurred twice during gastro-enteritis. Inhaled insulin was well tolerated and pulmonary function did not deteriorate. We conclude that severe resistance to subcutaneous insulin does not preclude sufficient absorption of insulin delivered by pulmonary.
van Alfen-van der Velden
A A E M
AA
Metabolic and Endocrine Diseases at Department of Pediatrics, Radboud University Medical Centre, Nijmegen, The Netherlands. j.vanalfen@cukz.umcn.nl
Noordam
C
C
de Galan
B E
BE
Hoorweg-Nijman
J J G
JJ
Voorhoeve
P G
PG
Westerlaken
C
C
D000280:Administration, Inhalation; D001786:Blood Glucose; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D055104:Infusions, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000009:adverse effects; D007333:Insulin Resistance; D008297:Male; D012141:Respiratory Tract Infections / Q000150:complications; D016896:Treatment Outcome
D001786:Blood Glucose; C473734:Exubera; D007004:Hypoglycemic Agents; D007328:Insulin